Luminex Announces Executive Management Changes
March 04 2008 - 1:15PM
Business Wire
Luminex Corporation (NASDAQ: LMNX), the worldwide leader in
multiplexed solutions, today announced the following executive
management organizational changes effective March 1, 2008. Randel
S. Marfin has been named to the new position of vice president of
strategic development, Gregory J. Gosch has been named vice
president of the Luminex Bioscience Group and Darin Leigh has been
named vice president of sales and marketing. �We are excited about
the growth of Luminex and the success of xMAP� technology in our
targeted market segments. These executive changes are in response
to our Company�s growth and will help us execute as we continue on
our anticipated growth trajectory,� said Patrick J. Balthrop,
president and chief executive officer of Luminex. �The changes were
made to help us explore new applications for xMAP Technology,
expand our business, and increase our market share in diagnostics
and life science research.� Strategic Development In the
newly-created position of vice president of strategic development,
Mr. Marfin will be responsible for identifying and building
business growth plans that will allow Luminex to access and
penetrate new high-value growth markets for our multiplexing
technology. Mr. Marfin�s initial focus will be in food safety and
animal health, an area that Luminex has entered with a recently
announced collaboration with Tyson Foods. Mr. Marfin joined Luminex
in June 1998 and previously served as vice president of the Luminex
Bioscience Group. He also formerly served as vice president, sales
and business development. Luminex Bioscience Group Mr. Gosch will
replace Mr. Marfin as vice president of the Luminex Bioscience
Group (LBG), which develops and markets innovative and novel
testing applications based on xMAP Technology. Since its creation
in 2005, the Luminex Bioscience Group has launched unique products,
including a pneumococcal assay that can test for the 14 most common
pneumococcal serotypes, and the FlexmiR�, line of microRNA
products. As vice president of the Luminex Bioscience Group, Mr.
Gosch will oversee the group�s business development, assay product
development, and manufacturing and commercial strategies. Sales and
Marketing Darin Leigh was previously senior director of sales and
marketing for diagnostics at Luminex. Mr. Leigh will replace Mr.
Gosch as vice president of sales and marketing. Mr. Leigh will
manage Luminex�s worldwide sales and marketing efforts and will be
responsible for driving increased adoption of Luminex�s xMAP
Technology across life science research and diagnostic markets.
Before joining Luminex, Mr. Leigh held a number of positions at
Abbott Laboratories in Europe and in the United States. Between
2001 and 2005 these included positions in global marketing, with
responsibilities for the launch of the Abbott Architect
immunochemistry systems. Previously, he held positions in sales
with laboratory suppliers in the United Kingdom. Mr. Leigh holds a
degree in Medical Laboratory Sciences from the University of
London. About Luminex Corporation Luminex Corporation develops,
manufactures and markets proprietary biological testing
technologies with applications throughout the diagnostic and life
sciences industries. The Company's xMAP� multiplex solutions
include an open-architecture, multi-analyte technology platform
that delivers fast, accurate and cost-effective bioassay results to
markets as diverse as pharmaceutical drug discovery, clinical
diagnostics and biomedical research, including the genomics and
proteomics research markets. The Company's xMAP technology is sold
worldwide and is already in use in leading clinical laboratories as
well as major pharmaceutical, diagnostic and biotechnology
companies. Further information on Luminex Corporation or xMAP
technology can be obtained at www.luminexcorp.com. Statements made
in this release that express Luminex's or management's intentions,
plans, beliefs, expectations or predictions of future events are
forward-looking statements. The words "believe," "expect,"
"intend," "estimate," "anticipate," "will," "could," "should" and
similar expressions are intended to further identify such
forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995. It is important to note that the
Company's actual results or performance could differ materially
from those anticipated or projected in such forward-looking
statements. Factors that could cause Luminex's actual results or
performance to differ materially include risks and uncertainties
relating to, among others, market demand and acceptance of
Luminex's products, the Company's dependence on strategic partners
for development, commercialization and distribution of products,
concentration of the Company's revenue in a limited number of
strategic partners, fluctuations in quarterly results due to a
lengthy and unpredictable sales cycle and bulk purchases of
consumables, Luminex's ability to scale manufacturing operations
and manage operating expenses, gross margins and inventory levels,
potential shortages of components, competition, the timing of
regulatory approvals, the implementation, including any
modification, of the Company's strategic operating plans, risks and
uncertainties associated with implementing our acquisition strategy
and the ability to integrate acquired companies or selected assets
into our consolidated business operations, as well as the risks
discussed under the heading "Risk Factors" in Luminex's Reports on
Forms 10-K and 10-Q, as filed with the Securities and Exchange
Commission. The forward-looking statements contained herein
represent the judgment of Luminex as of the date of this press
release, and Luminex expressly disclaims any intent, obligation or
undertaking to release publicly any updates or revisions to any
forward- looking statements to reflect any change in Luminex's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024